announced today the initiation of dosing in a Phase 1 scientific trial of APD811, a novel oral medication candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH. ‘An orally bioavailable prostacyclin receptor agonist could enhance the standard of look after patients with PAH, a life-threatening disorder,’ said William R. Shanahan, M.D., Arena’s Senior Vice President and Chief Medical Officer. ‘APD811 is usually a non-prostanoid substance; in preclinical studies, the oral uptake, half life and efficacy features suggest that it might give improved administration over current prostacyclin receptor therapies.’ This randomized, double-blind and placebo-controlled Phase 1 trial is planned to sign up up to 72 healthy adult volunteers and can evaluate the safety, tolerability and pharmacokinetics of single-ascending dosages of APD811.These endogenous cannabinoids appear to act on the reward pathways to the brain, to increase the incentive you get when you take food, but can have harmful effects. By increasing urge for food they can increase fat, which can bring about overweight or obesity. Drugs are apparently right now being developed that can increase the degrees of these chemicals in our brains by slowing the rate of which they disappear once they have been released,says Pertwee. Professor Pertwee in addition has found a method of possibly boosting the indicators in the mind that are generated by these endogenous cannabinoids.
Targacept and AstraZeneca enter agreement to build up and commercialize TC-5214 Targacept and AstraZeneca, Inc.